- The VERICI DX company and its Tutivia renal transplant rejection test have received MOLDX coverage.
- See a press release from April 2025.
- The MolDx "DEX" diagnostics exchange also shows the test as covered.
- And see also MolDx article A58019.
- Test web page here.
- An 88-patient study was published as Zhang et al. in 2019 - here.
Verici raised about $10M in 2022 and recently announced it plans new funding to support US market entry. On the web, its CLIA lab is in Franklin, TN.
According to CMS CR13023, the code was priced by gapfill in 2023. The fee schedule today is $2650.
##
(The 2025 CPT code book lists the test as "Tuteva" but other sources give the name as "Tutivia."
(I'm not sure the cutpoint between what AMA describes as a gene number (e.g. RNA expression of 18 genes) and what the AMA calls a "partial or select transcriptome." Zhang et al. appears to have focused in on a 17-gene, 12-housekeeping-gene set.)
##
